A design, recruitment, and baseline-characteristics report for the PREDIABETEXT cluster randomised trial of a digital diabetes-prevention intervention, with no efficacy outcomes yet reported. PICO summary and expert commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A secondary cost-consequence and budget impact analysis of the TELE-DD trial found a nurse-led telephone program for nonadherent Type 2 diabetics with comorbid depression became cheaper per glycaemically controlled patient by 12-18 months. PICO summary and expert commentary.
A 2-centre factorial RCT in 273 Chinese adults with type 2 diabetes found the Dnurse app did not significantly improve HbA1c attainment, though systolic blood pressure fell in the app arms. PICO summary and expert commentary.
A 6-month structured anti-inflammatory diet-and-exercise programme in 542 adults with prediabetes delayed diabetes onset but did not lower 8-year incidence. PICO summary and expert commentary.
A manufacturer-funded cost-effectiveness model found the MiniMed 780G closed-loop system cost-effective versus injections with isCGM in US type 1 diabetes at $100,000 per QALY (ICER $68,402 over 4 years, $38,842 lifetime). PICO summary and expert commentary.
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 met its equivalence margin for HbA1c reduction against reference dulaglutide. PICO summary and expert commentary.
A small mechanistic RCT (n=34) found ertugliflozin did not increase proximal tubular natriuresis (the primary outcome) but did reduce fluid volume and blood pressure by week 12. PICO summary and expert commentary.
A small open-label Spanish RCT found a digital education program added to GLP-1 therapy produced greater HbA1c, weight, and adherence gains than usual care over six months. PICO summary and expert commentary.
A small open-label randomised trial comparing dapagliflozin with insulin glargine as a fourth agent for glycaemic variability in type 2 diabetes inadequately controlled on triple therapy. PICO summary and expert commentary.
A small randomized trial compared perindopril plus indapamide against perindopril plus moxonidine (both with metformin) for left ventricular and renal protection in hypertension with prediabetes. PICO summary and expert commentary.